Compare Gilead Sciences, Inc. (GILD) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Garmin Ltd. — how do they compare? Gilead Sciences, Inc. trades at $134.6 (market cap $163.51B), while Garmin Ltd. trades at $247.79 (market cap $46.62B). The key difference: Gilead Sciences, Inc. is far larger — about 3.5× Garmin Ltd.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | GRMN | |
|---|---|---|
Market Cap | $163.51B | $46.62B |
Sector | Health | Technology |
52-Week High | $155.80 | $267.52 |
52-Week Low | $108.22 | $187.10 |
Enterprise Value | $178.05B | $44.09B |
Dividend Yield | 2.49% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Garmin (GRMN) trades at $247.96, up 2.72% on the day, with a neutral technical outlook and mixed earnings history including recent beats. Revenue growth is strong, reaching $7.25B in 2025, with robust profitability margins. Recent news highlights product innovations in aviation and marine electronics, supporting growth prospects. The stock is near its consensus price target of $281.50, indicating moderate upside potential from current levels.
The outlook for GRMN is cautiously optimistic, driven by solid fundamentals and innovation, but tempered by high valuation ratios and a majority hold rating from analysts. Key risks include competitive pressures and market volatility, while institutional sentiment remains mixed with limited insider activity noted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
